ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
August 16 2007 - 6:00AM
PR Newswire (US)
SCOTTSDALE, Ariz., Aug. 16 /PRNewswire-FirstCall/ -- IR BioSciences
Holdings, Inc. (OTC:IRBO) (BULLETIN BOARD: IRBO) today released a
letter to shareholders from Chairman and CEO Michael K. Wilhelm.
The purpose of the letter is to provide an update to its
shareholders on its subsidiary ImmuneRegen BioSciences' past year
of progress in the infectious disease and disaster preparedness
sectors. ImmuneRegen today has also filed a Form 8-K containing the
shareholder letter with the Securities and Exchange Commission. The
Form 8-K will be available on ImmuneRegen's website at
http://www.immuneregen.com/. The text of the letter is contained
below: Dear Shareholder, The previous year has been a noteworthy
one for ImmuneRegen BioSciences. Our scientific and business
activities have accelerated, and the company has recently announced
several noteworthy achievements and events such as acquisition of
study results, formation of collaborative and co-development
relationships as well as presentations at conferences and to the
FDA and NIH. The response by these agencies of the Department of
Health and Human Services remains quite positive as we continue to
deliver additional data in multiple areas of both scientific and
product development interest and having potential commercial
appeal. Current research programs include microbiological infection
such as anthrax bacillus, and influenza (including avian influenza
vaccine adjuvancy), in addition to radiation exposure (to both
lethal and sub-lethal/therapeutic doses). Results of our influenza
studies indicate that Viprovex(R) lowers viral load 90-99% in nose
and lungs of treated animals, as well as lowers the magnitude of
the virus-induced decreases in body weight and temperature. These
studies also indicate that Viprovex decreases the inflammatory
reaction in the lungs of infected animals, even in the presence of
Roche's influenza treatment and preventative, Tamiflu(R). The
company is continuing Tamiflu/Viprovex studies and they are
underway. Our radiation exposure studies, originally for biodefense
applications and terrorist attacks have been extended to include
potential cancer therapy applications. The radiation results have
indicated recovery of circulating white blood cells, and potential
stimulatory effects on stem cell proliferation and/or maturation.
Wound healing is also a market in which we anticipate forthcoming
success. Results from recently concluded studies indicate positive
effects in the area and we expect our drug candidate to continue to
demonstrate positive results as a potential growth factor. We also
believe that our recently announced relationships with companies
such as Uluru Inc. will expedite our efforts in wound healing. In
the opinion of management the current stock valuation does not
reflect the newly acquired data and relationships. We continue to
successfully develop business relationships with potential partners
and advance our product development activities in multiple,
sizeable markets. For example, the biodefense and pandemic
influenza market has been estimated at a combined total of $6.1
billion with seasonal influenza opportunities, as a therapeutic or
adjuvant to vaccination representing $2 billion total market
revenues in 2006. Cancer therapies for mitigating side effects to
toxic therapy and/or potentially playing a therapeutic role in the
stem cell area of medical treatments has a combined commercial
market worldwide estimated at $16.1 billion in revenue.
Additionally, we hope to achieve continual successful results in
the wound healing studies that we have currently partnered with
Uluru, Inc. We are collectively working toward adding additional
pharmaceutical company partnerships so we can develop effective
wound healing treatments that can theoretically address a broad
range of applications: diabetic ulcers, trauma, surgical wounds,
day to day cuts and scrapes. For 2006, the global wound care market
represented $7 billion in sales. A recent report by Global Industry
Analysts, Inc. dated July 9, 2007 stated that the wound care
products market is to reach $15.3 billion by 2010, driven by
sealants, growth factors, and skin replacements. Also, the US
market alone should be over $6 billion by 2010. We are very excited
about this work and are pleased as well as honored to be working
with our current partners in these areas. As our company continues
to hit milestones, it is our belief that we will have more
visibility to Wall Street, industry peers, potential partners and
the scientific community. The outside laboratories that have been
conducting research for us have been performing excellent work and
we appreciate the relationships that we have developed, maintain,
and may expand as we seek new and experienced partners in our
development efforts (most recently VaxGen and Uluru). I am looking
forward to announcing our next updates, results, conferences, etc.
The relationships we are forging today based on our current data as
well as anticipation of future data are very exciting and we hope
to be able to discuss formalizing them over the next few months.
Keep in touch with our updates by viewing our website
http://www.immuneregen.com/. We are available to answer your
queries and hope that you will send an email to me at or to Dr.
Siegel, Senior Director of Product Development and Regulatory
Affairs . We are happy to answer your corporate and scientific
questions. Keep in mind that our responses can only reflect that
information that is already publicly available. Best regards,
Michael K. Wilhelm Chief Executive Officer ImmuneRegen BioSciences,
Inc. IR BioSciences Holdings, Inc. 310-477-9500 DATASOURCE:
ImmuneRegen BioSciences, Inc. CONTACT: Michael K. Wilhelm, Chief
Executive Officer of ImmuneRegen BioSciences, Inc., IR BioSciences
Holdings, Inc., +1-310-477-9500, or Web site:
http://www.immuneregen.com/
Copyright